Jefferies joins brokers on Reckitt pharma float

Appointment could mean a potentially rare multi-billion-dollar mandate for the bank in Europe

Jefferies has been hired to work on the proposed spin-off of Reckitt Benckiser's pharmaceutical business – a potentially rare multi-billion-dollar mandate for the bank in Europe.

UK-based Reckitt Benckiser - which produces brands such as Clearasil spot cream, Durex condoms and French's mustard - is expected to spin-off its RB Pharmaceuticals arm next month, according to a statement. The division will be renamed Indivior and is expected to start trading in London on December 23.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump